[Form 4] Precigen, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Precigen CFO Harry Thomasian Jr. received a significant equity award in the form of 175,000 Restricted Stock Units (RSUs) on June 26, 2025. The RSUs represent the right to receive an equivalent number of Precigen common stock shares.

The vesting schedule for these RSUs is structured as follows:

• 50% vesting on May 23, 2026 (initial cliff vesting)
• Remaining 50% vesting in equal monthly installments over the subsequent three years

This Form 4 filing, signed by Donald P. Lehr as attorney-in-fact, indicates a long-term retention strategy for the CFO position. The RSUs were granted at no cost ($0) to the executive, representing a significant equity incentive aligned with shareholder interests. The award demonstrates Precigen's commitment to executive compensation through equity-based incentives.

Positive

• CFO Harry Thomasian Jr. received a significant equity incentive of 175,000 RSUs, representing a long-term retention package with 4-year vesting schedule
• The RSU grant structure with 50% cliff vesting followed by monthly vesting encourages long-term executive retention

Negative

• None.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thomasian Harry Jr.

(Last) (First) (Middle)

20374 SENECA MEADOWS PARKWAY

(Street)

GERMANTOWN MD 20876

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PRECIGEN, INC. [ PGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/26/2025		A		175,000		(2)	(2)	Common Stock	175,000	$0	175,000	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Precigen common stock.

2. The RSUs vest 50% on May 23, 2026 and in equal monthly installments for three years thereafter.

	/s/ Harry Thomasian, Jr., by Donald P. Lehr, as attorney-in-fact	06/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many restricted stock units (RSUs) did PGEN's CFO Harry Thomasian receive on June 26, 2025?

PGEN's CFO Harry Thomasian Jr. received 175,000 restricted stock units (RSUs) on June 26, 2025. Each RSU represents a contingent right to receive one share of Precigen common stock.

What is the vesting schedule for PGEN CFO's new RSU grant?

The RSUs granted to PGEN's CFO will vest 50% on May 23, 2026, with the remaining 50% vesting in equal monthly installments over the following three years.

What was the exercise price of PGEN CFO's RSU grant in June 2025?

The RSUs were granted at $0 exercise price, as indicated in the Form 4 filing. Each RSU represents a contingent right to receive one share of Precigen common stock upon vesting.

Who is the current Chief Financial Officer of PGEN as of June 2025?

Harry Thomasian Jr. is the Chief Financial Officer of Precigen (PGEN), as disclosed in the Form 4 filing. His business address is listed as 20374 Seneca Meadows Parkway, Germantown, MD 20876.